Pluri signs biologics API collaboration, cuts cash burn 30%, holds $56M cash

Pluri Inc.

New collaboration with European API manufacturer for liver/gastro drugs; revenue expected in coming months.
Annual cash burn reduced ~30% from $36M to ~$24M; $56M cash at June 30, 2022.
Plurinuva JV with Tnuva: first cultivated meat product in development; proof of concept this year, launch 2023.
Second tech collaboration after Tnuva; targets $366B biologics market, growing to $720B by 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.